drugset / Trial / NCT06258265

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

NCT06258265

Phase 1 Completed 120 enrolled Takeda
RandomizedParallel-groupQuadruple-blindOther

Summary

The main aim of this study is to find out how more than one dose of TAK-279 changes the heart-rate corrected QT (QTc) interval of healthy adults. A QTc interval is a measurement on an electrocardiogram (ECG) and shows the time when the heart contracts until it finishes relaxing. Other aims are to learn about the effect of several doses of TAK-279 on other ECG measurements of healthy adults, how the body of a healthy adult processes TAK-279 and moxifloxacin (pharmacokinetics), and to learn about the side effects of TAK-279 and how well it is tolerated when given to healthy adults. The participants will be given TAK-279 and moxifloxacin or a placebo for 7 days. During the study, participants will need to stay at the clinic for 10 days.

Timeline

Start
2024-04-29
Primary completion
2024-06-25
Completion
2024-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule
Subject Zasocitinib Small molecule

Indications

No indication recorded.